Supplemental Data

**Table S1. Human FMO3 polymorphism regions: PCR - RFLP products summary**

|  |  |  |  |
| --- | --- | --- | --- |
| ***FMO3*** **genotype** | **Accession no.** | **Primer sequence** | **Length of PCR products (bp)** |
| E158K | rs2266782 | F: 5’-CATCATgTgTATCCCAACCTACCAgAA-3’  R: 5’-gTgAAAAgTgAgAAATACATggCAg-3’ | 277 |
| V257M | rs1736557 | F: 5’-gggTgCTCACCAgAATATCCAC-3’  R: 5’-gCCATAgTTTTCATgCTTgAA-3’ | 249 |
| E308G | rs2266780 | F: 5’-TCCgTAAAgCCTAACgTgAAggAATTCACTg-3’  R: 5’-CTTgTgCTgCCCAgCgggACTg-3’ | 283 |

F, forward; R, reverse

**Table S2. Classification of patients according to cytochrome P450 2C19 genotype**

|  |  |  |  |
| --- | --- | --- | --- |
| **CYP2C19 genotype** | **CYP2C19 phenotype** | **Observed frequency, %** | **Number** |
| \*2/\*2, \*3/\*3, \*2/\*3 | PM | 10 | 36 |
| \*2/\*1, \*3/\*1, \*2/\*17, \*3/\*17 | IM | 46 | 165 |
| \*1/\*1 | EM | 26 | 93 |
| \*17/\*17, \*17/\*1 | UM | 18 | 65 |

PM, Poor metabolizer; IM, Intermediate metabolizer; EM, Extensive metabolizer; UM, Ultra-rapid metabolizer.

**Table S3. The patients were reclassified according to FMO3 genotypes.**

|  |  |
| --- | --- |
| **FMO3 genotype** | **Whole population**  **(n = 165)** |
| WT | 66 |
| E158K | 33 |
| E308G | 34 |
| V257M | 32 |